
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics is poised for significant growth, driven by an increase in Chromium reaction volumes, which indicates a robust market presence despite ongoing pricing pressures in the industry. The company is projected to experience substantial growth in consumables revenue, with estimates suggesting a 5-19 times increase by 2027, outpacing instrument revenue growth. Additionally, a forecasted production growth of over 60% quarter-over-quarter and 50% half-over-half as Media Luna ramps up through 2026 supports a positive outlook for the company's future financial performance.
Bears say
10x Genomics (TXG) is facing significant challenges, including a contraction in revenue in 2024 driven by double-digit pricing pressure and flat to declining volume growth, with market recovery not anticipated until 2027. The company reported disappointing Q4 earnings, missing EPS expectations and providing a full-year revenue outlook that fell below analyst forecasts. Additionally, the stock has experienced a substantial decline of over 90% since its peak in 2021, indicating that market expansion has not met prior expectations.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares